Global Pandemic Influenza Vaccine Market Size By Vaccine Type (Quadrivalent, Trivalent), By Age Group(Adult and Pediatric), By Technology(Egg- Based and Cell culture or Recombinant-based) , By Geographic Scope And Forecast

Pandemic Influenza Vaccine Market Size And Forecast

Pandemic Influenza Vaccine Market size was valued at USD 8.01 Billion in 2021 and is projected to reach USD 13.57 Billion by 2030, growing at a CAGR of 6.69% from 2023 to 2030.

The Pandemic Influenza Vaccine is used for the prevention of respiratory disease caused by influenza viruses specifically, influenza A and B viruses. Generally, it is a flu, influenza A viruses are separated by type hemagglutinin (H) and neuraminidase (N). The influenza vaccine includes inactivated or killed strains of the influenza virus, these antibodies have protection against infections. It widely finds its application in the regeneration of organs and tissues, pharmaceuticals, and others. The Global Pandemic Influenza Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Pandemic Influenza Vaccine Market Definition

Influenza, also known as flu, is a contagious respiratory illness caused by the influenza viruses that infect the nose, throat, and especially the lungs. It causes mild to severe illness and sometimes can lead to death. The key factors driving the demand for the market are the increase in awareness about the pandemic influenza viruses and the increasing government initiatives for vaccination against influenza. The influenza vaccines are made to safeguard against three different flu viruses (trivalent) including influenza A H1N1 virus, influenza A H3N2 virus, and one B virus.

However, the trivalent vaccines did not cover the entire type B virus, and therefore quadrivalent vaccines were made later. Another addition of the B virus to the vaccine aims to administer broader protection against circulating flu viruses. The proliferation of Pandemic Influenza Vaccine Market is growing rapidly in the USA due to factors such as increased disease awareness, government regulations, and policies favoring vaccine consumption.

Moreover, the Asia Pacific market for influenza vaccine is expanding due to increased coverage area and unlocking the untapped potential, and the rising of government awareness programs. The global Pandemic Influenza Vaccine Market is consolidated with major players dominating the market share. The entries are restricted in the market due to strict regulatory compliance requirements. The competitive landscape details strategies, products, and investments being done by key players in numerous technologies and companies to boost their market presence.

Global Pandemic Influenza Vaccine Market Overview

The Pandemic Influenza Vaccine Market is experiencing tremendous growth as a result of effective communication between prescribers such as physicians and patients. Additionally, the upsurge of pandemic influenza is another issue supplying the expansion of the market. Moreover, advanced technology and in-depth studies are propelling market growth. However, the problems associated with the development of vaccines and government regulatory compliance are the factors that are affecting the market growth.

The outbreak of COVID-19 has affected all the healthcare segments, except the market studied. As it affects a patient’s respiratory system, they must take vaccines for safety purposes. As a result, the demand for influenza vaccines has increased. Since there was a nationwide lockdown, biologists and researchers were unable to work from their laboratories, which has hindered the new introduction of vaccines into the market. The growing number of government initiatives to increase awareness regarding the medications and prevention of influenza has been the key market driver for influenza vaccines.

Moreover, major healthcare companies are investing large amounts of capital and time in the development of advanced therapy in the form of vaccines. According to the Centre for Disease Control and Prevention (CDC), seasonal influenza viruses are constantly mutating, due to which vaccines also need to be modified accordingly. This factor is driving the expansion of the Pandemic Influenza Vaccine Market. The huge cost involved in research and development and the long timeline required for the introduction of a new vaccine into the market may hinder the market growth for influenza vaccines.

Global Pandemic Influenza Vaccine Market Segmentation Analysis

The Global Pandemic Influenza Vaccine Market is segmented on the basis of Vaccine Type, Age Group, Technology, And Geography.

Pandemic Influenza Vaccine Market, By Vaccine Type

• Quadrivalent
• Trivalent

To Get Summarized Market Report By Vaccine Type-

On the basis of Vaccine Type, the Global Pandemic Influenza Vaccine Market has been segmented into Quadrivalent and Trivalent. Quadrivalent dominated the pandemic influenza vaccine market in 2021. The market growth of the quadrivalent vaccination category is primarily driven by rising product approvals and new launches. Furthermore, the introduction of novel vaccines has contributed to the growth of the quadrivalent segment.

Pandemic Influenza Vaccine Market, By Age Group

• Adult
• Pediatric

To Get Summarized Market Report By Age Group-

Based on Age Group, the market is bifurcated into Adult and Pediatric. Adult-based accounted for the largest market share in 2021. This dominance is attributed to higher vaccination doses given to adults to protect them against Pandemic Influenza Vaccine disease.

Pandemic Influenza Vaccine Market, By Technology

• Egg- Based
• Cell culture or Recombinant-based

To Get Summarized Market Report By Technology-

On the basis of Technology, the Global Pandemic Influenza Vaccine Market has been segmented into Egg- Based and Cell culture or Recombinant-based. Egg- Based is expected to dominated the pandemic influenza vaccine market over the forecast period. The key benefits of the egg-based platform are its outstanding production capacity, which can produce an estimated 1.5 billion doses yearly, and its low manufacturing cost, which makes the vaccine available to everyone in the world.

Pandemic Influenza Vaccine Market, By Geography

• North America
• Europe
• The Asia Pacific
• Rest of the world

To Get Summarized Market Report By Geography-

On the basis of regional analysis, the Global Pandemic Influenza Vaccine Market is classified into Mexico, Europe, Asia Pacific, and Rest of the world. Asia-Pacific is expected to hold the largest market share of the Pandemic Influenza Vaccine over the forecast. The growing government support in the form of grant funding, the rising emergence of viral diseases, increasing research & development by top markets, and the introduction of new vaccines into the market account for most of the Asia Pacific market share projected for the growth of the market in this region over the projected period.

Key Players

The “Global Pandemic Influenza Vaccine Market” study report provides valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, Sanofi S.A., AstraZeneca, Bio Diem, Seqirus, Emergent Bio Solutions Inc, Sinovac Biotech Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• March 2021, Sanofi announced to invest USD 736.9 million for its Canadian vaccine facility to upsurge the supply of influenza vaccines in Canada, the US, and Europe. This facility will provide additional antigen and filling capacity of Sanofi’s Fluzone High-Dose Quadrivalent influenza vaccine, to increase supply in these countries.
• February 2020, BIODIEM announced the approval of Changchun BCHT Biotechnology CO, LAIV vaccine by the Chinese National Medical Products.
• SINOVAC received a production license China National Medical Products Administration in June 2020 for a quadrivalent influenza vaccine (NMPA).
• Seqirus, a global leader in influenza prevention and a business of CSL Limited, has announced that the FDA has granted supplemental approval of AUDENZ (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to assist protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.

Report Scope

Top Trending Reports

Research Methodology of Market Research